ArticleJAMA neurology2026
Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials.
Article in JAMA neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Preventing irreversible disability accumulation is a primary treatment goal in multiple sclerosis (MS). Objective: To assess 10-year safety and efficacy of ocrelizumab (OCR) in patients with relapsing MS (RMS). Design, Setting, and Participants: In 2 phase 3 multicenter randomized clinical trials (OPERA I and II), patients were randomized to OCR or interferon beta-1a (IFN) throughout a 2-year double-blind period (DBP) and entered an open-label extension (OLE) to receive OCR for up to an additional 8 years. Study periods were August 2011 to December 2022, with clinical cutoff on July 15, 2023. Data analyses were run between March 2023 and May 2026. Patients with RMS, aged 18 to 55 years, with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, and at least 1 relapse within the year before screening were eligible for inclusion. Interventions: OCR (600 mg every 24 weeks) or IFN (44 µg 3 times weekly) in the DBP, then OCR during the OLE. Main Outcomes and Measures: Outcomes included time to onset of 48-week confirmed disability progression (CDP) or progression independent of relapse activity (PIRA); time to reach EDSS score of 4.0 and 6.0; relapse rates; and incidence of adverse events (AEs) and serious AEs. Results: A total of 1656 patients were randomized, and 1651 patients received either OCR (n = 825) or IFN (n = 826). A total of 1325 patients (80.0%) entered the OLE, of whom 853 (64.4%) completed the studies. A total of 1093 of 1656 patients (66.0%) were female; mean (SD) baseline age was 37.1 (9.2) years vs 37.2 (9.2) years in the OCR vs IFN arms, respectively. Over 10 years, continuous OCR (OCR-OCR) significantly reduced the hazard of 48-week CDP by 24% compared with delayed initiation (IFN-OCR; hazard ratio, 0.76; 95% CI, 0.61-0.95; P = .02), with 680 patients (82.2%) receiving OCR-OCR remaining free of 48-week CDP and 712 (86.1%) free of PIRA. OCR-OCR treatment reduced the hazard of progressing to key disability milestones, including EDSS of 4.0 (34%; hazard ratio, 0.66; 95% CI, 0.43-1.03; P = .06) and 6.0 (43%; hazard ratio, 0.57; 95% CI, 0.40-0.82; P = .002), with 502 (93.3%) and 774 (94.2%) retaining scores less than 4.0 and 6.0, respectively. In patients receiving OCR-OCR, relapse rates decreased from 0.139 at year 1 to 0.016 at year 10. Rates of AEs and SAEs, including serious infections, did not increase over the 8-year OLE. Conclusions and Relevance: In the OPERA I and II randomized clinical trials, continuous OCR treatment over 10 years provided greater benefit in preserving function than a 2-year delay in initiating OCR, reinforcing the importance of early high-efficacy treatment. Trial Registrations: ClinicalTrials.gov Identifiers: NCT01247324 and NCT01412333.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.